Peer Review History

Original SubmissionSeptember 14, 2021
Decision Letter - Dong Keon Yon, Editor

PONE-D-21-29410Maternal mortality associated with COVID-19 in Brazil in 2020 and 2021: comparison with non-pregnant women and menPLOS ONE

Dear Dr. Gonçalves,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 02 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Dong Keon Yon, MD, FACAAI

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

4. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

"This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [INV-027961]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

"YES - Bill & Melinda Gates Foundation (Seattle, USA), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ - Brasília, Brazil), and Fundação de amparo à pesquisa e inovação do Estado do Espírito Santo (FAPES - Espírito Santo, Brazil) are funding source. Their role is to support the research."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5. Thank you for stating the following in your Competing Interests section:  

"No author have. competing interests"

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now 

 This information should be included in your cover letter; we will change the online submission form on your behalf.

Additional Editor Comments:

I congratulate you on your mesmerizing work. I have raised several concerns.

#1. Documenting that pregnant and postpartum women are at a higher risk of developing severe forms of COVID-19 isessential for prioritizing them in health care strategies.

Please cite references.

#2. Please explain plausible basic mechanism. (i.e., ACE2, SARS-CoV-2, pregnancy, molecular mechanism)

#3. The authors have to provide the policy implication regarding vaccination. Please see the landmark previos study.

Hwang J, Park SH, Lee SW, Lee SB, Lee MH, Jeong GH, Kim MS, Kim JY, Koyanagi A, Jacob L, Jung SY, Song J, Yon DK, Shin JI, Smith L. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score. Eur Heart J. 2021 Sep 21:ehab592. doi: 10.1093/eurheartj/ehab592. Epub ahead of print. PMID: 34545400; PMCID: PMC8500026.

#4. Limitation

Pregnancy patients was associted with depression [1] and low level physical activity [2], which may mediated the COVID-19 effect.

Please disscuss this in the limitation section and cite the top-tier papers below.

[1] Fond G, Nemani K, Etchecopar-Etchart D, Loundou A, Goff DC, Lee SW, Lancon C, Auquier P, Baumstarck K, Llorca PM, Yon DK, Boyer L. Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021 Jul 27:e212274. doi: 10.1001/jamapsychiatry.2021.2274. Epub ahead of print. PMID: 34313711; PMCID: PMC8317055.

[2] Lee SW, Lee J, Moon SY, Jin HY, Yang JM, Ogino S, Song M, Hong SH, Abou Ghayda R, Kronbichler A, Koyanagi A, Jacob L, Dragioti E, Smith L, Giovannucci E, Lee IM, Lee DH, Lee KH, Shin YH, Kim SY, Kim MS, Won HH, Ekelund U, Shin JI, Yon DK. Physical activity and the risk of SARS-CoV-2 infection, severe COVID-19 illness and COVID-19 related mortality in South Korea: a nationwide cohort study. Br J Sports Med. 2021 Jul 22:bjsports-2021-104203. doi: 10.1136/bjsports-2021-104203. Epub ahead of print. PMID: 34301715; PMCID: PMC8300550.

Again, I congratulate your excellent paper.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: A very valuable article in my opinion, this article can be published as a scientific reference for many related research, the method of posing the problem was effective and linking the problem with the results was strong, the presentation of the information was consistent and understandable, the statistical method is strong and convincing, my only comment, I may need more introduction to understand the problem In the region of Brazil. I highly recommend this search

Reviewer #2: Good use of the routine data to answer important program question. Covid 19 pandemic has impacted public health globally. National level technical committees are faced with the questions to identify high risk groups in order to priortise public health interventions. Women with pregnancy were not included for covid vaccination due to lack of data and evidence. Later countries included this group based on the clinical evidence. Researchers in this manuscript have created evidence that pregnancy is a high risk group. This is important despite all its limitations.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Issam J. A Abu Qeis

Reviewer #2: Yes: Dr Arun Kumar Aggarwal

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

1. #1. Documenting that pregnant and postpartum women are at a higher risk of developing severe forms of COVID-19 is essential for prioritizing them in health care strategies.

Please cite references.

Response: Thank you for your comment. The following text has been included in the current version of the manuscript in the discussion section.

“Pregnant and postpartum women have been shown to be at a higher risk of developing more severe illnesses related to the SARS-COV-2 infection as highlighted by Zambrano et al. in November 2020 [11]. This data was further corroborated by a systematic review published by Wastnedge et al, also suggesting a higher vulnerability of the pregnant population to the infection [27]. Other studies also validateours, suggesting that pregnant women are at a higher risk for ICU care during the 2021 pandemic. [13,16].”

References:

Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(44):1641-1647.

Wastnedge EAN, Reynolds RM, van Boeckel SR, Stock SJ, Denison FC, Maybin JA, Critchley HOD. Pregnancy and COVID-19. Physiol Rev. 2021 Jan 1;101(1):303-318. doi: 10.1152/physrev.00024.2020. Epub 2020 Sep 24. PMID: 32969772; PMCID: PMC7686875.

Nakamura-Pereira M, Andreucci CB, Menezes M., Knobel R. et al. Worldwide maternal deaths due to COVID-19: A brief review. Gynecology & Obstetrics. 2020; 152: 148-150.

Takemoto MLS, Menezes M de O de O, Andreucci CB, et al. Clinical characteristics and risk factors for mortality in obstetric patients with severe COVID-19 in Brazil: a surveillance database analysis. BJOG 2020; 127: 1618–26.

2. Please explain plausible basic mechanism. (i.e., ACE2, SARS-CoV-2, pregnancy, molecular mechanism)

Response:Thank you for your suggestion. The following text has been included in the current version of the manuscript.

Recent studies suggest that the expression of angiotensin converting enzyme 2 (ACE 2), a receptor used by SARS-CoV-2 in human placentas, could increase maternal population susceptibility to infection. [1] ACE 2 receptors actively participate in necessary hemodynamic adaptations through pregnancy, when consumed by SARS-CoV-2 this could increase risk for placental dysfunction increasing risk of worst outcomes after infection [29,30].

References :

29. Nobrega Cruz N. A., Stoll D., Casarini D. E., Bertagnolli M. Role of ACE2 in pregnancy and potential implications for COVID-19 susceptibility. ClinSci (Lond) 13 August 2021; 135 (15): 1805–1824. doi: https://doi.org/10.1042/CS20210284

30. Todros T, Masturzo B, De Francia S. COVID-19 infection: ACE2, pregnancy and preeclampsia. Eur J ObstetGynecolReprod Biol. 2020;253:330. doi:10.1016/j.ejogrb.2020.08.007

3. The authors have to provide the policy implication regarding vaccination. Please see the landmark previos study.

Hwang J, Park SH, Lee SW, Lee SB, Lee MH, Jeong GH, Kim MS, Kim JY, Koyanagi A, Jacob L, Jung SY, Song J, Yon DK, Shin JI, Smith L. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score. Eur Heart J. 2021 Sep 21:ehab592. doi: 10.1093/eurheartj/ehab592. Epub ahead of print. PMID: 34545400; PMCID: PMC8500026.

Thank you for your comment. We did not provide any information regarding vaccination policy for pregnant and postpartum women because the studied period is previous to the maternal population vaccination start. The vaccination in Brazil for maternal population started in May 2021.

The following text has been included in the current version of the manuscript (Discussion):

“The period studied is prior to the start of vaccination of the maternal population. Vaccination in Brazil for the maternal population began in May 2021. Our study confirms the worse evolution of the population of pregnant and postpartum women when compared to non-pregnant women and men and may be useful in guiding this population regarding the importance of vaccination against COVID-19. Most references point out that the probability of complications arising during pregnancy due to SARS-COV2 infection is greater than those related to vaccination [31,32]. Currently, the maternal and postpartum population is considered at high risk for SARS-COV2 infection and should be among the priorities for vaccination.”

31. Rasmussen et al. COVID-19 Vaccines and Pregnancy. American College of Obstetricians and Gynecologists. 2021; 137 (3).

32. Russell, F. M. and Greenwood, B. Who should be prioritised for COVID-19 vaccination? Human Vaccin Immunother. 2021; 17(3): 1317-1321.

4. Pregnancy patients was associted with depression [1] and low level physical activity [2], which may mediated the COVID-19 effect.

Please disscuss this in the limitation section and cite the top-tier papers below.

Thank you for your suggestion. The following remarks were added to our discussion into the limitation section.

“The presence of health disorders and the role of physical activity were not analyzed in the present study. Increased mortality in patients with mental disorders has been described by Fond et al. in previous studies, OR (1.38 [95% CI, 1.15-1.65]; P < .05). [33] Physical activity was also identified as a protective factor, both for aerobic and muscular strengthening activities (0.02% vs 0.08%; aRR 0.24; 95% CI 0.05 to 0.99) [34]”

33. Fond G, Nemani K, Etchecopar-Etchart D, Loundou A, Goff DC, Lee SW, Lancon C, Auquier P, Baumstarck K, Llorca PM, Yon DK, Boyer L. Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021 Jul 27:e212274. doi: 10.1001/jamapsychiatry.2021.2274. Epub ahead of print. PMID: 34313711; PMCID: PMC8317055.

34. Lee SW, Lee J, Moon SY, Jin HY, Yang JM, Ogino S, Song M, Hong SH, AbouGhayda R, Kronbichler A, Koyanagi A, Jacob L, Dragioti E, Smith L, Giovannucci E, Lee IM, Lee DH, Lee KH, Shin YH, Kim SY, Kim MS, Won HH, Ekelund U, Shin JI, Yon DK. Physical activity and the risk of SARS-CoV-2 infection, severe COVID-19 illness and COVID-19 related mortality in South Korea: a nationwide cohort study. Br J Sports Med. 2021 Jul 22:bjsports-2021-104203. doi: 10.1136/bjsports-2021-104203. Epub ahead of print. PMID: 34301715; PMCID: PMC8300550.

Reviewer #2:

I may need more introduction to understand the problem in the region of Brazil.

Thank you for your comment. The following text was added to our paper.

“In early 2021, the maternal mortality rate seems to be even higher, even though the knowledge about the disease and the treatment tools have evolved. A recent study by Takemoto et. al, demonstrated that the mortality rate was about two times higher for the maternal population in 2021 (15.6%), when compared to 2020 (7.4%), but these authors did not compare the group of pregnant and postpartum women with the groups of men and women , as proposed in this study (7.4%) [15,16]. “

15. Takemoto MLS, Menezes M de O de O, Andreucci CB, et al. Higher case fatality rate among obstetric patients with COVID-19 in the second year of pandemic in Brazil: do new genetic variants play a role? medRxiv doi:https://doi.org/10.1101/2021.05.06.21256651.

16. Takemoto MLS, Menezes M de O de O, Andreucci CB, et al. Clinical characteristics and risk factors for mortality in obstetric patients with severe COVID-19 in Brazil: a surveillance database analysis. BJOG 2020; 127: 1618–26.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Dong Keon Yon, Editor

Maternal mortality associated with COVID-19 in Brazil in 2020 and 2021: comparison with non-pregnant women and men

PONE-D-21-29410R1

Dear Dr. Gonçalves,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Dong Keon Yon, MD, FACAAI

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

I congratulate you on your mesmerizing work.

Reviewers' comments:

Formally Accepted
Acceptance Letter - Dong Keon Yon, Editor

PONE-D-21-29410R1

Maternal mortality associated with COVID-19 in Brazil in 2020 and 2021: comparison with non-pregnant women and men

Dear Dr. Gonçalves:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Dong Keon Yon

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .